TCL Archive Mihich to Be Sixth New NCAB appointee; Centers Worried About Core Grants, Role In 200 AD Goals May 25, 1984
TCL Archive FDA approval of two colon cancer therapies triggers discussion among researchers, clinicians about best treatment and clinical trial designs. CMS reimbursement pending; costs to U.S. of the new drugs could be billions per year, but some predict dramatic increases in survival. March 5, 2004
TCL Archive Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials September 26, 2014
